<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Topotecan [(S)-9-dimethylaminomethyl-10-hydroxycamptothecin <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>; SK&amp;F 104864-A, NSC 609699], a water soluble semisynthetic analogue of the <z:chebi fb="13" ids="22315">alkaloid</z:chebi> <z:chebi fb="0" ids="27656">camptothecin</z:chebi>, is a potent <z:chebi fb="0" ids="50276">topoisomerase I inhibitor</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) cells, causes rapid apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> despite high-level expression of bcl-2 protein, and inhibits ALL cell in vitro clonogenic growth in a dose-dependent fashion </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, topotecan elicited potent antileukemic activity in three different <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> (<z:mp ids='MP_0002536'>SCID</z:mp>) mouse models of human poor prognosis ALL and markedly improved event-free survival of <z:mp ids='MP_0002536'>SCID</z:mp> mice challenged with otherwise fatal doses of human <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells at systemic drug exposure levels that can be easily achieved in children with <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>